A 2018 literature review summarizes the various ways patients can consume cannabis (orally, topically, etc.) and the pain reductions associated with each method. The review focuses on the treatment of multiple sclerosis, cancer, anorexia, arthritis, and other painful disorders.
Cannabis and Psychosis: Are We any Closer to Understanding the Relationship?
Despite the constant technological gains in medicine, there is still insufficient information and knowledge about who is at risk of developing cannabis psychosis prior to an individual’s exposure to cannabis. Controlled research is limited due to the legal status of cannabis but the growing number of states legalizing medicinal and recreational use of cannabis will likely provide a naturalistic experiment that will produce a prevention strategy for the condition. Current schizophrenia research is limited to western male populations and an overemphasis on the biological model; future research should extend to a more diverse population and sociocultural factors that may lead to schizophrenia.
Title of study: Cannabis use as a risk factor for causing motor vehicle crashes: a prospective study
After legalization in 2018, many Canadian provinces implemented “zero tolerance” policies for drivers who have THC in their systems. But a new study from the University of British Columbia suggests that Canada’s drug-impaired driving laws may be unnecessarily strict. According to researchers, there is no link between THC levels below 5ng/mL and increased risk of car accidents.
Note: Considering the potentially grave risk to life and health for modern culture to make the wrong interpretation of the potential dangers of the effects of cannabis consumption on driving, it is critical for the industry to approach the circumstances with delicacy and diligence. Ideally, everyone involved will be motivated to learn as much as possible about the impact of cannabis on the risks of operating machinery and all will follow a cautious approach which will minimize the risk to all. To that end, it is important to consider and reconcile evidence from multiple perspectives.
Genome-wide association study implicates CHRNA2 in Cannabis Use Disorder
Roughly 9% of cannabis users become dependent. In a recent study, scientists identified a significant association between CHRNA2 gene expression and a diagnosis of Cannabis Use Disorder. In other words, genetics might help to explain why some people may find themselves more dependent upon cannabis than others.
A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain ECS
The cannabinoid system provides momentum to develop cannabinoid-based medications to treat inflammatory and neuropathic pain as researchers continue to find promising therapeutic targets. These new targets may lead to the formation of novel pain-relief medications that may serve well to alleviate pain for those suffering from cancer, multiple sclerosis, and fibromyalgia. Cannabis-based pain medicine is also being researched for opioid-sparing effects and effectiveness in reducing the necessary dose of opioids.
MA effectively outlawed the sale of any food products with CBD or products which make therapeutic claims. This is the result of FDA saying that CBD cannot be added to food or dietary supplements. In a state where cannabis is legally accessible, consumers and hemp farmers are very unhappy. What do you think? http://bit.ly/2IOtTRm
Benjamin Caplan, MDIn MA, despite being state-legal, FDA says CBD cannot be added to food or dietary supplements. What now?
Crossing the Line: Care of a Pediatric Patient with Intractable Seizures and Severe Neuropathic Pain in Absence of Access to Medical Marijuana
A recent case report discussing a six-year-old patient suffering from a seizure disorder has exposed the difficulty is receiving treatment across state lines. The patient was prescribed medical marijuana that alleviated the severity and duration of her seizures but was weaned off that medication when traveling to Nebraska for a therapeutic surgery due to the legal status in the state. This case study exposes the difficulty of treating patients across the country due to the legal variability of cannabis across states.
An interesting question brought up in this case study is how to handle palliative care in the absence of opioids and without synthetic products. A combination of massage, essential oils, and salt light therapies were able to compensate for medical marijuana, but not without great effort. Natural therapies like the ones administered here are costly and highlight the simplicity and effectiveness of medicinal cannabis.
A 2019 literature review summarizes the findings on cannabis use for patients with multiple sclerosis. Cannabis has been shown to aid a number of symptoms associated with multiple sclerosis, including chronic pain, spasticity, and problems with sleep. To learn more, check out our video adaptation below: